<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/33E5EB17-8A9B-43F4-AA33-1FBF483ECEE2"><gtr:id>33E5EB17-8A9B-43F4-AA33-1FBF483ECEE2</gtr:id><gtr:name>Baxter</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9907604A-7E4B-4EA4-A2C5-501329E525D2"><gtr:id>9907604A-7E4B-4EA4-A2C5-501329E525D2</gtr:id><gtr:name>Synovo GmbH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/764B70DC-0DB5-4BB7-BAA7-D4772245C908"><gtr:id>764B70DC-0DB5-4BB7-BAA7-D4772245C908</gtr:id><gtr:name>Chroma Therapeutics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/52E9D771-EB72-40D6-952A-5E388663AE26"><gtr:id>52E9D771-EB72-40D6-952A-5E388663AE26</gtr:id><gtr:name>Immodulon Therapeutics Ltd, London</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Barts Cancer Institute</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/33E5EB17-8A9B-43F4-AA33-1FBF483ECEE2"><gtr:id>33E5EB17-8A9B-43F4-AA33-1FBF483ECEE2</gtr:id><gtr:name>Baxter</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9907604A-7E4B-4EA4-A2C5-501329E525D2"><gtr:id>9907604A-7E4B-4EA4-A2C5-501329E525D2</gtr:id><gtr:name>Synovo GmbH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/764B70DC-0DB5-4BB7-BAA7-D4772245C908"><gtr:id>764B70DC-0DB5-4BB7-BAA7-D4772245C908</gtr:id><gtr:name>Chroma Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/52E9D771-EB72-40D6-952A-5E388663AE26"><gtr:id>52E9D771-EB72-40D6-952A-5E388663AE26</gtr:id><gtr:name>Immodulon Therapeutics Ltd, London</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/52EE4ED8-2F15-4BB0-BB4E-1779D2CD5390"><gtr:id>52EE4ED8-2F15-4BB0-BB4E-1779D2CD5390</gtr:id><gtr:firstName>Thorsten</gtr:firstName><gtr:surname>Hagemann</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601867"><gtr:id>F0F094B1-B30A-404E-B346-05AC20FFFFF6</gtr:id><gtr:title>'Re-educating' the tumour-associated macrophages in ovarian cancer.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0601867</gtr:grantReference><gtr:abstractText>Cancers are not just a mass of malignant cells, but instead can be viewed as ?rogue? tissues made up of many normal cells as well. Malignant cells use these normal cells to help them grow and spread. One normal cell type that is particularly common and abundant in tumours is the macrophage. Although macrophages, as part of the immune system, are capable of recognising and destroying tumour cells, in advanced cancer the malignant cells ?corrupt? the macrophages, turning them into cells that actually promote instead of inhibiting the growth of the cancer. The aim of this project is to understand exactly how tumour cells corrupt macrophages and to find ways to switch these tumour macrophages from ?bad? cells to ?good?. This work involves experiments of cells in dishes in the lab, in mouse models of cancer and in samples obtained from cancer patients. An intervention that switches ?bad? macrophages in tumours into ?good? cells may be a powerful way of helping a cancer patient?s immune system attack their disease.</gtr:abstractText><gtr:technicalSummary>Most human and murine cancers posses an abundant population of tumour-associated macrophages, TAM, whose actions are thought to promote tumour development and spread. At the other end of the spectrum of macrophage activity, ?classically? activated macrophages are capable of destroying tumour cells, but this does not appear to happen in the tumour microenvironment of advanced cancer.
A series of preliminary experiments have led us to the hypothesis that the inflammatory cytokine TNF- , via the NF- B transcription factor complex, may maintain the tumour-promoting actions of TAM. 
The aim of this project is to investigate how TNF- signalling normally maintains the phenotype of TAM, with particular relevance to ovarian cancer; and to devise novel therapeutic approaches that may ?re-educate? macrophages in vivo to recognise and destroy tumour cells.
Using a novel tumour cell:macrophage co-culture system developed in our laboratory, a syngeneic mouse model of intraperitoneal ovarian cancer, and human ovarian cancer samples, we will first define components of TNF- system that are involved in maintenance of the TAM phenotype and assess the in vivo relevance of TNF- and NF- B for maintenance of the TAM phenotype. Using this information we will then conduct signature-based prediction assays to identify other modulators of TAM phenotype and define novel therapeutic targets. Finally we will use our knowledge to devise therapeutic strategies to ?re-educate? TAM in vivo. First, we will assess the ability of ?re-educated? macrophages, adoptively transferred to mice with advanced ovarian cancer, to mediate tumour regression and switch the host TAM phenotype. Second, will use adenoviral delivery of constructs that will inhibit TNF- or NF- B signalling in these mice. Finally we will develop an in vitro method that will allow us to screen existing drugs and a compound library for substances that may be capable of ?re-educating? TAM in vivo in patients with advanWe believe that these approaches could provide a powerful way to switch the immunosuppressive microenvironment of advanced cancer into one that encourages tumour cell destruction by host cells and development of useful adaptive immune responses against the tumours. Such manipulations would complement existing chemotherapy or biological therapies for ovarian and other cancers.</gtr:technicalSummary><gtr:fund><gtr:end>2011-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>881198</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Baxter</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Baxter Healthcare</gtr:department><gtr:description>Baxter monoclonal antibody screen</gtr:description><gtr:id>542531D3-63B4-409F-B977-1B0FF19DD78A</gtr:id><gtr:impact>Phase 1 protocol (1st in man) in preparation for one antibody in cancer. Pre-clinical data collection completed.</gtr:impact><gtr:outcomeId>rfw7jcYctYi-1</gtr:outcomeId><gtr:piContribution>We established xenograft and syngeneic mouse models of pancreatic cancer of the past 3 years. This is a collaboration were we provide our model resource to test therapeutics in a pre-clinical model.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Targeting IKKbeta signalling in macrophages</gtr:description><gtr:id>26898D30-5178-4518-844C-D64820DD757B</gtr:id><gtr:impact>This is an MRC CASE studentship, awarded in 2009 which started on the 1st of Oct 2009. Publications or other output: Publication in preparation (manuscript at stage of proof reading).</gtr:impact><gtr:outcomeId>F6A3174761E-1</gtr:outcomeId><gtr:partnerContribution>MRC CASE studentship, support comes also in form of the respective IKK compound</gtr:partnerContribution><gtr:piContribution>MRC studentship is now running for 1 year. Drug screen in pancreatic cancer model on its way investigating myeloid targeting strategies in combination with chemotherapy. Publication in preparation.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chroma Therapeutics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Macrophage specific targeting</gtr:description><gtr:id>A65A430A-A30E-4926-A52F-A22F7E2EED27</gtr:id><gtr:impact>Chroma has a compound which enables us to target specifically macrophages. Currently we are preparing the protocol for a phase 1 trial in cancer. Additionally we established mouse models to test the compounds.</gtr:impact><gtr:outcomeId>567435511ED-1</gtr:outcomeId><gtr:partnerContribution>Chroma has a compound which enables us to target specifically macrophages.</gtr:partnerContribution><gtr:piContribution>We used the respective compounds for our research to target tumour associated macrophages. Several compounds have been tested in the lab.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Synovo GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Research and Development Synovo GmbH</gtr:department><gtr:description>Macrophage targeting</gtr:description><gtr:id>1221E970-AA7B-4049-B149-A9DB0D297D8C</gtr:id><gtr:impact>contractually confidential</gtr:impact><gtr:outcomeId>hWDPo6hAjDc-1</gtr:outcomeId><gtr:piContribution>test therapeutics in vivo in preclinical models</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Infection and Immunity</gtr:department><gtr:description>Exploring the innate and adaptive immune interface</gtr:description><gtr:id>FBEDF6CC-2BFD-4485-BDFB-02FE70541560</gtr:id><gtr:impact>Applying for MRC and CRUK project grant funding.</gtr:impact><gtr:outcomeId>pVabk38ybzz-1</gtr:outcomeId><gtr:partnerContribution>exchange of knowledge and skills to drive project.</gtr:partnerContribution><gtr:piContribution>We established and published about the importance of macrophage phenotypes in the tumour microenvironment. This led to the collaboration investigating the potential of combining the innate targeting approach by my group with the adaptive immune modulation by Hans Stauss and Emma Morris.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Immodulon Therapeutics Ltd, London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Immodulon</gtr:description><gtr:id>0ED8BC1E-1242-4C72-951C-7A042A9E71A2</gtr:id><gtr:impact>Just started with first in vivo experiments.</gtr:impact><gtr:outcomeId>ngQEXCh36WP-1</gtr:outcomeId><gtr:piContribution>immunomodulating compounds tested in vivo in murine genetic pancreatic cancer disease model (pre-clinical)</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Commentary to JEM Paper</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>41DD17A3-DCDF-4843-9915-D998411341DA</gtr:id><gtr:impact>The publication in J Ex Med attracted a Commentary in the same issue of the Journal.

Led to notification of group activity.</gtr:impact><gtr:outcomeId>5A9113E8D7A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Session Host NCRI 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>95BED5D6-5F20-40C5-82B2-8573851564F3</gtr:id><gtr:impact>150 conference participants joined my session at the NCRI on the tumour microenvironment; very well perceived discussion and presentation from high caliber national and international speakers

collaborations between the participants and industry</gtr:impact><gtr:outcomeId>qYdGkoTdgMS</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nature Reviews Immunology Highlight</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>72685CFA-387D-42AC-ACE8-331CCC9585BB</gtr:id><gtr:impact>Furthermore the J Ex Med paper attracted a 'Research Highlight' article in Nature Reviews Immunology.

International representation of the groups activity and lift of reputation.</gtr:impact><gtr:outcomeId>30B4E63BF58</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Club</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>C468E085-D0FD-4887-8B15-16B9BE2FF486</gtr:id><gtr:impact>This is an ongoing activity - members of the group run a science club at a primary school in London, Edith Neville School in Camden; one of the most deprived areas in London. During term we organize scientific education and experiments around the groups activity to enthuse pupils for medical science.

Impact more on a small scale through recognition by teachers and pupils.</gtr:impact><gtr:outcomeId>9A9DF8EACDB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture NCRI</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>3F6B32ED-C107-47F3-B2D8-A8F7BBF42194</gtr:id><gtr:impact>NCRI conference in Birmingham - invited lecture to present data on tumour associated macrophages

Collaboration with academia and industry.</gtr:impact><gtr:outcomeId>0DADD9FB38A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC showcase Oncology &amp; Cancer</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>C9295CCA-2920-4394-8883-66A10B9B7B6A</gtr:id><gtr:impact>Poster presentation at the MRC showcase 'Oncology &amp;amp; Cancer' in Manchester, Nov 2007. My poster presentation won the best poster prize at this showcase.

This activity led to an MRC application with Astra Zeneca which was unfortunately unsuccessful.</gtr:impact><gtr:outcomeId>50B179A22C7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Club</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>C44C0804-1696-4A1A-BC9F-467A53C023B5</gtr:id><gtr:impact>I run a science club in the Edith Neville Primary School in Camden which runs 6x/term and teaches about 10-12 pupils per term scientific skills and engages them in science.

To continue with this club as it made an impact on the outcome in science in this school.</gtr:impact><gtr:outcomeId>UiWNrzFCchW</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>QMUL PhD Studentship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Queen Mary University of London</gtr:fundingOrg><gtr:id>EAFFE15E-7F23-415E-8D2E-FCC3B56CA768</gtr:id><gtr:outcomeId>08BE32177D40</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>8000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Role of Ptch in Tumour Associated Macrophages in Ovarian Cancer</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>Queen Mary University of London</gtr:fundingOrg><gtr:id>E6EB64A0-B3F3-41A8-BDEF-DD9674865D9B</gtr:id><gtr:outcomeId>B505399594F0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99365</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>RAB Project Grant</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Queen Mary University of London</gtr:fundingOrg><gtr:id>60E7C6D0-F4DA-4FA6-B4A7-E62BE0F3CF26</gtr:id><gtr:outcomeId>9C7ED79A45D0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>226210</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Project Grant</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>1EAA50BE-EBE2-4B19-A7EA-C911F1692C5F</gtr:id><gtr:outcomeId>5DB0ADDF54F0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>140840</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC CASE Studentship</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>5FA034EC-6F49-40B6-B380-D077791A2F35</gtr:id><gtr:outcomeId>466974C68050</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Enhancing oncolytic adenovirus efficacy in pancreatic cancer by switching tumour-associated macrophages</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Pancreatic Cancer Research Fund</gtr:fundingOrg><gtr:id>18376E53-13CF-4F72-B9D0-C4062C500723</gtr:id><gtr:outcomeId>TYycjb8RNJB0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Ovarian Cancer Action Project Grant</gtr:description><gtr:end>2011-02-02</gtr:end><gtr:fundingOrg>Ovarian Cancer Action</gtr:fundingOrg><gtr:id>BA9548AA-04F7-40C2-A855-B3F0BECC8251</gtr:id><gtr:outcomeId>39DF96E20160</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NAC clinical trial Phase 1</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>FE118AB5-A94D-4858-85A4-ED90CD853361</gtr:id><gtr:outcomeId>ntoTKThuk4C0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Senior Fellowship</gtr:description><gtr:end>2017-11-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>B3E1C7EE-8FEF-4D5A-B09C-16FE9E78433F</gtr:id><gtr:outcomeId>S4ysEDtKNCH0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>8000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Mouse model of ovarian cancer</gtr:description><gtr:end>2010-05-02</gtr:end><gtr:fundingOrg>Queen Mary University of London</gtr:fundingOrg><gtr:id>055D0A63-3DDA-47EC-8E91-776C65577403</gtr:id><gtr:outcomeId>C8EB5D28BB80</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Luciferase expressing syngeneic ovarian cancer cells have been established to enable in situ imaging of disease progression.</gtr:description><gtr:id>927CEC2F-1889-4712-9610-E2B4C2D3E987</gtr:id><gtr:impact>Saves animals to study therpeutical therapies in a syngeneic model of ovarian cancer.</gtr:impact><gtr:outcomeId>0207013A0AE</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ID8 Luciferase Cell Line</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>primary cancer cell lines from a genetic murine model of pancreatic cancer with gene deletion for IKK and tnf have been developed.</gtr:description><gtr:id>E6191585-6F11-446D-B4DA-6ADC1E0A2A79</gtr:id><gtr:impact>developing strategies for early detection, biomarkers and therapeutics for pancreatic cancer.</gtr:impact><gtr:outcomeId>TvPXRFrXAvd</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>pancreatic cancer cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Tumour associated macrophages have been isolated from ID8 tumour bearing mice at different time points of disease development. Macrophage RNA has been analysed by Affymetrix chips.</gtr:description><gtr:id>47EB7094-5F0E-4769-814D-915E503D12A7</gtr:id><gtr:impact>This approach will help to development new therapeutic targets and biomarkers.</gtr:impact><gtr:outcomeId>1E7DB7D894A</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Transcriptomics</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4CEB1AC5-5FF9-4C80-A25E-2B9192695284</gtr:id><gtr:title>The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f880434fe71f517be824fe857dc1c022"><gtr:id>f880434fe71f517be824fe857dc1c022</gtr:id><gtr:otherNames>Charles KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>fnz3fFn2Ny4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15C7FF45-C2DF-4B1A-BA8F-B5F9FFF090BC</gtr:id><gtr:title>Cancer. Sex, cytokines, and cancer.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9840fd94b2f1df7980e154fd24bf3379"><gtr:id>9840fd94b2f1df7980e154fd24bf3379</gtr:id><gtr:otherNames>Lawrence T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>DCA3AD38496</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FF6BA93-CEEB-43A7-AAC8-DD7897EF6F6C</gtr:id><gtr:title>Measurement of tumor cytolysis by macrophages.</gtr:title><gtr:parentPublicationTitle>Current protocols in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e692cebfef18a87cb2221fcd8b708690"><gtr:id>e692cebfef18a87cb2221fcd8b708690</gtr:id><gtr:otherNames>Esc?rcio-Correia M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1934-3671</gtr:issn><gtr:outcomeId>NutyoGuKT1o</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>762F1418-3C73-4B1B-B45E-1F8F3F2EF242</gtr:id><gtr:title>Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51e4debc3b141cb5dd9af32bec651864"><gtr:id>51e4debc3b141cb5dd9af32bec651864</gtr:id><gtr:otherNames>Schuttrumpf S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>6D9D1F80593</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4AC03EA-109C-4599-BBA1-D625735B2453</gtr:id><gtr:title>Molecular profiling of cervical cancer progression.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/916556e206095ba8de824bfd28f7859f"><gtr:id>916556e206095ba8de824bfd28f7859f</gtr:id><gtr:otherNames>Hagemann T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>656B8923345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD78490A-D25F-4E89-9974-D06DAA9DB4D7</gtr:id><gtr:title>Crosstalk between the canonical NF-?B and Notch signaling pathways inhibits Ppar? expression and promotes pancreatic cancer progression in mice.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95256e93b114409ed456084e10b6bf5b"><gtr:id>95256e93b114409ed456084e10b6bf5b</gtr:id><gtr:otherNames>Maniati E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>b6rRpqzZjWZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47E30EE4-C89B-4C7C-B9C7-631117EC2DEA</gtr:id><gtr:title>Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/916556e206095ba8de824bfd28f7859f"><gtr:id>916556e206095ba8de824bfd28f7859f</gtr:id><gtr:otherNames>Hagemann T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>6C0C059CB33</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>282D7FA2-3598-486A-98BF-56B2C8C3831A</gtr:id><gtr:title>Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/916556e206095ba8de824bfd28f7859f"><gtr:id>916556e206095ba8de824bfd28f7859f</gtr:id><gtr:otherNames>Hagemann T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>C27AFE7CA49</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AE6E4BC-9D30-4B12-A600-953A34E8529E</gtr:id><gtr:title>The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fe09e7ce4e63bf13625cea1564da9e2"><gtr:id>7fe09e7ce4e63bf13625cea1564da9e2</gtr:id><gtr:otherNames>Kulbe H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>2452944C651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34BE08DA-6A0C-4E9A-B14B-C5B6A134D76D</gtr:id><gtr:title>Human ovarian surface epithelial cells immortalized with hTERT maintain functional pRb and p53 expression.</gtr:title><gtr:parentPublicationTitle>Cell proliferation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7480c8c1ba19183a54c1ea59c8db926d"><gtr:id>7480c8c1ba19183a54c1ea59c8db926d</gtr:id><gtr:otherNames>Li NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0960-7722</gtr:issn><gtr:outcomeId>9D894C2E244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C314F3C-537F-486B-B0A7-E34BF4917FBB</gtr:id><gtr:title>Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57aaaf68aab5e88079f0a409904ce38a"><gtr:id>57aaaf68aab5e88079f0a409904ce38a</gtr:id><gtr:otherNames>Szlosarek PW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>7F71E32D77E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7AD2F83-0A04-44BF-9870-F2CDA906E6F4</gtr:id><gtr:title>A distinct DNA methylation profile associated with microsatellite and chromosomal stable sporadic colorectal cancers.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64422312237a5e8ce1775da0a02b8097"><gtr:id>64422312237a5e8ce1775da0a02b8097</gtr:id><gtr:otherNames>Silver A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>rwcXLyeLrKU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0CFFADF-E5F3-432D-8E3B-04C0FCDE4D97</gtr:id><gtr:title>Up for Mischief? IL-17/Th17 in the tumour microenvironment.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95256e93b114409ed456084e10b6bf5b"><gtr:id>95256e93b114409ed456084e10b6bf5b</gtr:id><gtr:otherNames>Maniati E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>ZvURfinmWwF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB48A4D9-7BD1-448A-BD3E-6F9AD9530D3F</gtr:id><gtr:title>Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84db36d10d8d63b857de7dd5f8ecb2aa"><gtr:id>84db36d10d8d63b857de7dd5f8ecb2aa</gtr:id><gtr:otherNames>Pukrop T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>771E63C925E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB848E53-89A6-4BB9-B459-EC7A45723603</gtr:id><gtr:title>Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a24041dcc02bfe4287b91bef6a22bab"><gtr:id>4a24041dcc02bfe4287b91bef6a22bab</gtr:id><gtr:otherNames>Hallam S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>72F0505EFE5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C7882C6-A01F-496E-B91A-52AEBC062088</gtr:id><gtr:title>Inflammation and cancer: a double-edged sword.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/916556e206095ba8de824bfd28f7859f"><gtr:id>916556e206095ba8de824bfd28f7859f</gtr:id><gtr:otherNames>Hagemann T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>9D3D663A26E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBA570FA-4888-48CE-8E97-ECF2CD78BD7B</gtr:id><gtr:title>Stromal endothelin B receptor-deficiency inhibits breast cancer growth and metastasis.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc717644cd184c2556c6eb7af5b3f417"><gtr:id>bc717644cd184c2556c6eb7af5b3f417</gtr:id><gtr:otherNames>Binder C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>F18FC4DA08B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2826682-F4A5-49BC-989E-D683C15F6367</gtr:id><gtr:title>&amp;quot;Re-educating&amp;quot; tumor-associated macrophages by targeting NF-kappaB.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/916556e206095ba8de824bfd28f7859f"><gtr:id>916556e206095ba8de824bfd28f7859f</gtr:id><gtr:otherNames>Hagemann T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>E4B3A8557FA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>978F97AC-9D9C-417D-A396-42A495D6305D</gtr:id><gtr:title>Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/916556e206095ba8de824bfd28f7859f"><gtr:id>916556e206095ba8de824bfd28f7859f</gtr:id><gtr:otherNames>Hagemann T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>67EBB4B04C9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FFA1494-A495-4A97-AFC0-0117FD2B89D4</gtr:id><gtr:title>Investigating macrophage and malignant cell interactions in vitro.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/916556e206095ba8de824bfd28f7859f"><gtr:id>916556e206095ba8de824bfd28f7859f</gtr:id><gtr:otherNames>Hagemann T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>D9735705644</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29C5CB0E-3769-4213-87F8-796E3BC6DB5E</gtr:id><gtr:title>A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fe09e7ce4e63bf13625cea1564da9e2"><gtr:id>7fe09e7ce4e63bf13625cea1564da9e2</gtr:id><gtr:otherNames>Kulbe H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>YvNH9sisSsC</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601867</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>